Similarities and differences between European guidelines for the management of postmenopausal osteoporosis.
European guidelines
Fracture risk
Postmenopausal osteoporosis
Journal
Archives of osteoporosis
ISSN: 1862-3514
Titre abrégé: Arch Osteoporos
Pays: England
ID NLM: 101318988
Informations de publication
Date de publication:
05 Sep 2024
05 Sep 2024
Historique:
received:
01
03
2024
accepted:
15
08
2024
medline:
5
9
2024
pubmed:
5
9
2024
entrez:
5
9
2024
Statut:
epublish
Résumé
We conducted a review of 10 national guidelines from five EU countries to identify similarities or differences in recommendations for the management of patients with osteoporosis. We found general alignment of key recommendations; however, there are notable differences, largely attributed to country-specific approaches to risk assessment and reimbursement conditions. The classification of fracture risk is critical for informing treatment decisions for post-menopausal osteoporosis. The aim of this review was to summarise 10 national guidelines from five European countries, with a focus on identifying similarities or differences in recommendations for the management of patients with osteoporosis. We summarised the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Disease-International Osteoporosis Foundation guidelines and reviewed guidelines from France, Germany, Italy, Spain and the UK. The approach to risk assessment differed across the guidelines. In France, and Spain, risk assessment was based on DXA scans and presence of prior fractures, whereas UK, German and Italian guidelines recommended use of a validated risk tool. These differences led to distinct definitions of very high and high-risk patients. Guidelines aligned in recommending antiresorptive and anabolic agents as pharmacologic options for the management of osteoporosis, with sequential treatment recommended. There was agreement that patients at high or very high risk of fracture or with severe osteoporosis should receive anabolic agents first, followed by antiresorptive drugs. Variations were identified in recommendations for follow up of patients on anti-osteoporosis therapies. Reimbursement conditions in each country were a key difference identified. Criteria for risk assessment of fractures differ across European guidelines which may impact treatment and access to anabolic agents. Harmonisation across EU guidelines may help identify patients eligible for treatment and impact treatment uptake. However, country-specific reimbursement and prescribing processes may present a challenge to achieving a consistent approach across Europe.
Identifiants
pubmed: 39235671
doi: 10.1007/s11657-024-01441-z
pii: 10.1007/s11657-024-01441-z
doi:
Substances chimiques
Bone Density Conservation Agents
0
Types de publication
Journal Article
Review
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
84Informations de copyright
© 2024. The Author(s).
Références
Kanis JA, Norton N, Harvey NC et al (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16:82. https://doi.org/10.1007/s11657-020-00871-9
doi: 10.1007/s11657-020-00871-9
pubmed: 34080059
pmcid: 8172408
National Institute for Health and Care Excellence CKS. Osteoporosis - prevention of fragility fractures. Last revised April 2023. Available at: https://cks.nice.org.uk/topics/osteoporosis-prevention-of-fragility-fractures/ . Accessed June 2024
Föger-Samwald U, Dovjak P, Azizi-Semrad U et al (2020) Osteoporosis: pathophysiology and therapeutic options. Excli J 19:1017. https://doi.org/10.17179/EXCLI2020-2591
doi: 10.17179/EXCLI2020-2591
pubmed: 32788914
pmcid: 7415937
Tarantino U, Iolascon G, Cianferotti L et al (2017) Clinical guidelines for the prevention and treatment of osteoporosis: summary statements and recommendations from the Italian society for orthopaedics and traumatology. J Orthop Traumatol 18:3–36. https://doi.org/10.1007/s10195-017-0474-7
doi: 10.1007/s10195-017-0474-7
pubmed: 29058226
pmcid: 5688964
National Institute for Health and Care Excellence CG146. Osteoporosis: assessing the risk of fragility fracture. Published August 2012. Updated February 2017. Available at: https://www.nice.org.uk/guidance/cg146 . Accessed June 2024
Gregson CL, Armstrong DJ, Bowden J et al (2022) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 17:58. https://doi.org/10.1007/s11657-022-01061-5
doi: 10.1007/s11657-022-01061-5
pubmed: 35378630
pmcid: 8979902
International Osteoporosis Foundation. Scorecard for osteoporosis in Europe. SCOPE 2021 Summary Report. Available at: https://www.osteoporosis.foundation/sites/iofbonehealth/files/2022-01/SCOPE%20Summary%20Report.pdf . Accessed June 2024
Barańska A, Drop B, Religioni U et al (2023) Assessment of awareness and knowledge about osteoporosis in relation to health prevention among patients treated in osteoporosis clinics. J Clin Med 12:6157. https://doi.org/10.3390/jcm12196157
doi: 10.3390/jcm12196157
pubmed: 37834801
pmcid: 10573914
Kanis JA, Cooper C, Rizzoli R, Reginster J-Y (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3–44. https://doi.org/10.1007/s00198-018-4704-5
doi: 10.1007/s00198-018-4704-5
pubmed: 30324412
Kanis JA, Harvey NC, McCloskey E et al (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31:1–12. https://doi.org/10.1007/s00198-019-05176-3
doi: 10.1007/s00198-019-05176-3
pubmed: 31720707
Willers C, Norton N, Harvey NC et al (2022) Osteoporosis in Europe: a compendium of country-specific reports. Arch Osteoporos 17:23. https://doi.org/10.1007/s11657-021-00969-8
doi: 10.1007/s11657-021-00969-8
pubmed: 35079919
pmcid: 8789736
National Institute for Health and Care Excellence. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update). Available at: https://www.nice.org.uk/guidance/indevelopment/gid-ng10216 . Accessed June 2024
Briot K, Roux C, Thomas T et al (2018) 2018 update of French recommendations on the management of postmenopausal osteoporosis. Joint Bone Spine 85:519–530. https://doi.org/10.1016/j.jbspin.2018.02.009
doi: 10.1016/j.jbspin.2018.02.009
pubmed: 29654947
Pfeil A, Lange U (2024) Update DVO-Leitlinie 2023 „Prophylaxe, Diagnostik und Therapie der Osteoporose bei postmenopausalen Frauen und bei Männern ab dem 50. Lebensjahr“ – Was ist neu für die Rheumatologie? [Update on the DVO Guideline 2023 “Prophylaxis, diagnosis and treatment of osteoporosis in postmenopausal women and in men aged over 50”-What's new for rheumatology?]. Z Rheumatol 83:401–406. https://doi.org/10.1007/s00393-024-01495-x
doi: 10.1007/s00393-024-01495-x
pubmed: 38512355
pmcid: 11147822
Nuti R, Brandi ML, Checchia G et al (2019) Guidelines for the management of osteoporosis and fragility fractures. Intern Emerg Med 14:85–102. https://doi.org/10.1007/s11739-018-1874-2
doi: 10.1007/s11739-018-1874-2
pubmed: 29948835
Riancho JA, Peris P, González-Macías J, Pérez-Castrillón JL (2022) Executive summary clinical practice guideline of postmenopausal, glucocortcioid-induced and male osteoporosis (2022 update). Spanish Society for Bone and Mineral Metabolism Investigation (SEIOMM). Revista Clínica Española (English Edition) 222:432–439. https://doi.org/10.1016/j.rceng.2021.12.008
doi: 10.1016/j.rceng.2021.12.008
Riancho J, Peris P, González-Macías J, Pérez-Castrillón J (2022) Guías de práctica clínica en la osteoporosis postmenopáusica, glucocorticoidea y del varón (actualización 2022). Rev Osteoporos Metab Miner 14:13–33. https://doi.org/10.4321/S1889-836X2022000100003
doi: 10.4321/S1889-836X2022000100003
International Osteoporosis Foundation. New FRAXplus® (Beta version) illustrates potential of refined risk factor information entered to the world’s most widely used fracture risk assessment tool. Available at: https://www.osteoporosis.foundation/news/new-fraxplusr-beta-version-illustrates-potential-refined-risk-factor-information-entered . Accessed June 2024
Giangregorio LM, Leslie WD, Lix LM et al (2012) FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 27:301–308. https://doi.org/10.1002/jbmr.556
doi: 10.1002/jbmr.556
pubmed: 22052532
Corrao G, Biffi A, Porcu G et al (2023) Executive summary: Italian guidelines for diagnosis, risk stratification, and care continuity of fragility fractures 2021. Front Endocrinol 14:1137671. https://doi.org/10.3389/fendo.2023.1137671
doi: 10.3389/fendo.2023.1137671
FRAXplus®. Available at: https://fraxplus.org/ . Accessed June 2024
(2012) NICE CG146. Osteoporosis: assessing the risk of fragility fracture. Available at: https://www.nice.org.uk/guidance/cg146 . Accessed June 2024
Glüer C-C, Engelke K, Thomasius F (2023) Das konzept des DVO frakturrisikorechners. Osteologie 32:123–132. https://doi.org/10.1055/a-2053-7047
doi: 10.1055/a-2053-7047
Schmidmaier R, Hadji P, Kern P et al (2023) Recommendations for the pharmacological treatment of osteoporosis – update 2023 of the German osteoporosis guideline. Osteologie 32:115–122. https://doi.org/10.1055/a-2034-6086
doi: 10.1055/a-2034-6086
Bliuc D, Nguyen ND, Milch VE et al (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513–521
doi: 10.1001/jama.2009.50
pubmed: 19190316
Krupa K, Parmar M, Delo LF (2023) Romosozumab. In: StatPearls. StatPearls Publishing, Treasure Island (FL)
European Commission Approves EVENITY® (romosozumab) for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture. Available at: https://www.amgen.com/newsroom/press-releases/2019/12/european-commission-approves-evenity-romosozumab-for-the-treatment-of-severe-osteoporosis-in-postmenopausal-women-at-high-risk-of-fracture . Accessed June 2024
Foessl I, Dimai HP, Obermayer-Pietsch B (2023) Long-term and sequential treatment for osteoporosis. Nat Rev Endocrinol 19:520–533. https://doi.org/10.1038/s41574-023-00866-9
doi: 10.1038/s41574-023-00866-9
pubmed: 37464088
Leder BZ, Tsai JN, Uihlein AV et al (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. The Lancet 386:1147–1155. https://doi.org/10.1016/S0140-6736(15)61120-5
doi: 10.1016/S0140-6736(15)61120-5
Anastasilakis AD, Makras P, Yavropoulou MP et al (2021) Denosumab discontinuation and the rebound phenomenon: a narrative review. J Clin Med 10:152. https://doi.org/10.3390/jcm10010152
doi: 10.3390/jcm10010152
pubmed: 33406802
pmcid: 7796169
Tsourdi E, Langdahl B, Cohen-Solal M et al (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11–17. https://doi.org/10.1016/j.bone.2017.08.003
doi: 10.1016/j.bone.2017.08.003
pubmed: 28789921
Eladynos (abaloparatide) - summary of product characteristics
Diagnosi, stratificazione del rischio e continuità assistenziale delle Fratture da Fragilità. Available at: https://www.iss.it/-/snlg-fratture-da-fragilita . Accessed June 2024
National Institute for Health and Care Excellence (2019) 2019 surveillance of menopause: diagnosis and management (NICE guideline NG23) [Internet]. Available at: https://www.nice.org.uk/guidance/ng23 . Accessed June 2024